(Q37337951)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19043452%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

review article

1 reference

title

Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19043452%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19043452%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Anwesha Dey

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19043452%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Vinay Tergaonkar

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19043452%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

1 December 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19043452%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Drug Discovery

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19043452%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19043452%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19043452%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

1031-1040

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19043452%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

cites work

Surfing the p53 network

1 reference

p53 in health and disease

31 March 2020

1 reference

MDM2 inhibitors for cancer therapy

31 March 2020

1 reference

Activators and target genes of Rel/NF-kappaB transcription factors

31 March 2020

1 reference

Inhibitors of NF-kappaB signaling: 785 and counting

31 March 2020

1 reference

Shaping the nuclear action of NF-kappaB

31 March 2020

1 reference

Integrating cell-signalling pathways with NF-kappaB and IKK function

31 March 2020

1 reference

Inflammation and cancer: how hot is the link?

31 March 2020

1 reference

NF-kappaB and cancer-identifying targets and mechanisms

31 March 2020

1 reference

NF-kappaB functions as a tumour promoter in inflammation-associated cancer

31 March 2020

1 reference

Transcriptional cross talk between NF-kappaB and p53.

31 March 2020

1 reference

p53 and NF-kappaB crosstalk: IKKalpha tips the balance

31 March 2020

1 reference

Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB

31 March 2020

1 reference

p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy

31 March 2020

1 reference

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

31 March 2020

1 reference

Can we rationally design promiscuous drugs?

31 March 2020

1 reference

How many drug targets are there?

31 March 2020

1 reference

Cyclin-dependent kinase pathways as targets for cancer treatment

31 March 2020

1 reference

Small-molecule cyclin-dependent kinase modulators

31 March 2020

1 reference

Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1

31 March 2020

1 reference

Activation of p53 by roscovitine-mediated suppression of MDM2 expression

31 March 2020

1 reference

Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses

31 March 2020

1 reference

In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)

31 March 2020

1 reference

In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.

31 March 2020

1 reference

The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway

31 March 2020

1 reference

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma

31 March 2020

1 reference

A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival.

31 March 2020

1 reference

Roscovitine, olomoucine, purvalanol: inducers of apoptosis in maturing cerebellar granule neurons

31 March 2020

1 reference

Roscovitine modulates DNA repair and senescence: implications for combination chemotherapy.

31 March 2020

1 reference

R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy.

31 March 2020

1 reference

Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis

31 March 2020

1 reference

Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine.

31 March 2020

1 reference

Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor

31 March 2020

1 reference

Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9.

31 March 2020

1 reference

Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors

31 March 2020

1 reference

p53 pathway in renal cell carcinoma is repressed by a dominant mechanism.

31 March 2020

1 reference

Quinacrine inhibits the epidermal dendritic cell migration initiating T cell-mediated skin inflammation

31 March 2020

1 reference

The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination

31 March 2020

1 reference

Small-molecule inhibitor which reactivates p53 in human T-cell leukemia virus type 1-transformed cells

31 March 2020

1 reference

Acridine derivatives activate p53 and induce tumor cell death through Bax.

31 March 2020

1 reference

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

31 March 2020

1 reference

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

31 March 2020

1 reference

Nutlin-3 inhibits the NFkappaB pathway in a p53-dependent manner: implications in lung cancer therapy.

31 March 2020

1 reference

Updates on p53: modulation of p53 degradation as a therapeutic approach

31 March 2020

1 reference

Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics.

31 March 2020

1 reference

IkappaB kinase-independent IkappaBalpha degradation pathway: functional NF-kappaB activity and implications for cancer therapy

31 March 2020

1 reference

Differential regulation of NF-kappaB activation and function by topoisomerase II inhibitors

31 March 2020

1 reference

Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B.

31 March 2020

1 reference

Cisplatin mimics ARF tumor suppressor regulation of RelA (p65) nuclear factor-kappaB transactivation

31 March 2020

1 reference

Distinct roles of IkappaB proteins in regulating constitutive NF-kappaB activity.

31 March 2020

1 reference

Nuclear transport as a target for cell growth

31 March 2020

1 reference

Nuclear Retention of IκBα Protects It from Signal-induced Degradation and Inhibits Nuclear Factor κB Transcriptional Activation

31 March 2020

1 reference

Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma

31 March 2020

1 reference

Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease

31 March 2020

1 reference

Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis

31 March 2020

1 reference

HTLV-1 associated myelopathy in an HTLV-1 and HBV double carrier family: report of a case and the mode of vertical transmission of both viruses

31 March 2020

1 reference

HTLV-I associated myelopathy, a new clinical entity.

31 March 2020

1 reference

HTLV-I Tax induces a novel interaction between p65/RelA and p53 that results in inhibition of p53 transcriptional activity

31 March 2020

1 reference

Inactivation of p53 by human T-cell lymphotropic virus type 1 Tax requires activation of the NF-kappaB pathway and is dependent on p53 phosphorylation.

31 March 2020

1 reference

Inhibition of methyltransferases results in induction of g2/m checkpoint and programmed cell death in human T-lymphotropic virus type 1-transformed cells

31 March 2020

1 reference

Methyltransferase inhibition induces p53-dependent apoptosis and a novel form of cell death

31 March 2020

1 reference

Activated AKT regulates NF-kappaB activation, p53 inhibition and cell survival in HTLV-1-transformed cells

31 March 2020

1 reference

Cross-talks between cyclooxygenase-2 and tumor suppressor protein p53: Balancing life and death during inflammatory stress and carcinogenesis

31 March 2020

1 reference

Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy

31 March 2020

1 reference

Changes of NF-kB, p53, Bcl-2 and caspase in apoptosis induced by JTE-522 in human gastric adenocarcinoma cell line AGS cells: role of reactive oxygen species

31 March 2020

1 reference

Molecular targets of dietary agents for prevention and therapy of cancer

31 March 2020

1 reference

An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells.

31 March 2020

1 reference

Sesquiterpene lactone parthenolide suppresses tumor growth in a xenograft model of renal cell carcinoma by inhibiting the activation of NF-kappaB.

31 March 2020

1 reference

Angiogenesis: an organizing principle for drug discovery?

31 March 2020

1 reference

Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome.

31 March 2020

1 reference

Cancer-related inflammation

31 March 2020

1 reference

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth

31 March 2020

1 reference

The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest

31 March 2020

1 reference

TNP-470 inhibits oxidative stress, nitric oxide production and nuclear factor kappa B activation in a rat model of hepatocellular carcinoma

31 March 2020

1 reference

NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase

31 March 2020

1 reference

Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit

31 March 2020

1 reference

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

31 March 2020

1 reference

Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors

31 March 2020

1 reference

p53- and Mdm2-Independent Repression of NF-κB Transactivation by the ARF Tumor Suppressor

31 March 2020

1 reference

Role of NF-κB in p53-mediated programmed cell death

31 March 2020

1 reference

Regulation of p53 tumour suppressor target gene expression by the p52 NF-kappaB subunit

31 March 2020

1 reference

Prospective therapeutic applications of p53 inhibitors

31 March 2020

1 reference

A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy

31 March 2020

1 reference

Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies

31 March 2020

1 reference

PML is a direct p53 target that modulates p53 effector functions

31 March 2020

1 reference

Promyelocytic leukemia protein sensitizes tumor necrosis factor alpha-induced apoptosis by inhibiting the NF-kappaB survival pathway

31 March 2020

1 reference

Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells

31 March 2020

1 reference

Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders

31 March 2020

1 reference

Detection of the p53 response in zebrafish embryos using new monoclonal antibodies

31 March 2020

1 reference

Zebrafish IkappaB kinase 1 negatively regulates NF-kappaB activity.

31 March 2020

1 reference

Expression of the Bcl-3 proto-oncogene suppresses p53 activation

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD2759

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19043452%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference